Figure 1.
Recombinant soluble HLA-DO expression and characterization.
(A) Design and sequence of the recombinant soluble HLA-DO α and β chain constructs. (B) Soluble co-expressed DO/DM complex was purified using Mags.DO5 monoclonal antibody affinity column. Four replicate samples were resolved on Bis-Tris SDS-PAGE gels in decreasing protein concentrations. Gels were blotted to PVDF membranes and stained for DO (left, anti-His and anti-HA) and DM (right, anti-FLAG and anti-c-Myc) specific tags. Data shown are representative of three independent experiments. (C) SPR sensograms of DR (red trace), DM (blue trace) and co-expressed DM/DO complexes (Mags.DO5 purified) (green trace) binding to anti-HA antibody coupled chip surfaces. (D) SPR sensgrams of binding of DR (red trace), DM (blue trace) and DM/DO (Mags.DO5 purified) (green trace) to anti-His antibody coupled chip surfaces. (E) SPR sensograms showing binding of DM/DO (Ni-NTA purified) (green trace), DM (red trace), and DM/DO (Ni-NTA purified) pre-bound to soluble Mags.DO5 (blue trace) to Mags.DO5 antibody coupled chip surfaces. The SPR experiments are representative of at least two independent trials.
Figure 2.
Soluble recombinant DO recognizes soluble recombinant DM.
(A) DO (Ni-NTA purified) was immobilized on an anti-His antibody surface (blue trace). After a brief wash, DM was injected over the captured DO (green trace). A control injection of DM over anti-His antibody surface (red trace) showed no non-specific binding. Data shown are representative of six independent experiments. (B) DO (Ni-NTA purified) binding to DM immobilized by anti-FLAG antibody surface in concentrations ranging from 0.01 to 10 µM in separate experiments.
Figure 3.
DO diminishes binding of peptides to DR1 molecules.
(A) Association (left) and dissociation (right) of CII(259–273) peptide to DR1 molecules with no accessory molecules (black squares), with DM (red dots), with DO (green triangles), or both DO and DM (blue triangles) over the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence Units) associated with the control samples incubated >10 hours in the absence of DR1 were measured: CII(259–273) peptide alone, 3996; CII(259–273)+DM, 1026; CII(259–273)+DO, 3326; CII(259–273)+DM+DO, 8278. (B) Association (left) and dissociation (right) of HA(anchorless) peptide to DR1 molecules with no accessory molecules (black squares), with DM (red dots), DO (green triangles) or both DO and DM (blue triangles) over the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence Units) associated with the control samples incubated >10 hours in the absence of DR1 were measured: HA(anchorless) peptide alone, 3364; HA(anchorless)+DM, 1334; HA(anchorless)+DO, 1558; HA(anchorless)+DM+DO, 1726. Data shown are representative of at least three independent experiments.
Figure 4.
DO can increase the binding of peptides to DR1 molecules.
(A) Association (left) and dissociation (right) of HA(306–318) peptide to DR1 molecules with no accessory molecules (black squares), with DM (red dots), DO (green triangles) or both DO and DM (blue triangles) over the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence Units) associated with the control samples incubated >10 hours in the absence of DR1 were measured: HA(306–318) peptide alone, 1390; HA(306–318)+DM, 1376; HA(306–318)+DO, 3316; HA(306–318)+DM+DO, 9236. (B) Association (left) and dissociation (right) of H5N1-HA1(259–274) flu peptide to DR1 molecules with no accessory molecules (black squares), with DM (red dots), DO (green triangles) or both DO and DM (blue triangles) over the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence Units) associated with the control samples incubated >10 hours in the absence of DR1 were measured: H5N1-HA1(259–274) peptide alone, 1312; H5N1-HA1(259–274)+DM, 1250; H5N1-HA1(259–274)+DM+DO, 9012. (C) Prolonged 96 hour dissociation experiment of HA(306–318) peptide from DR1 molecules with DM (red dots) or both DO and DM (blue triangles). Data shown are representative of at least three independent experiments.
Table 1.
The initial rates of peptide/DR1 complex formation for tested peptides with and without accessory molecules.
Figure 5.
The observed effect of DO on peptide presentation is DO specific and can manifest in complex with DM.
(A) Association of HA(Y308A) peptide to DR1 molecules in the presence of coinfected DM/DO complex (Ni-NTA purified). The peptide binding experiment was performed with no accessory molecules (black squares), with DM (red dots), DM/DO (green triangles), or both DM/DO and DM (blue triangles) over the course of 10 hours. The fluorescence signals (Arbitrary Fluorescence Units) associated with the control samples incubated >10 hours in the absence of DR1 were measured: HA(Y308A) peptide alone, 1140; HA(Y308A)+DM, 894; HA(Y308A)+DM/DO, 1404; HA(Y308A)+DM+DM/DO, 1944. (B) DO was depleted from a DO stock by immunoprecipitation via Ni-NTA followed by Mags.DO5 resin. The depleted sample was used instead of DO in reactions measuring HA(anchorless) peptide/DR complex formation in the presence or absence of DM after 5 hours of incubation. The fluorescence intensity of peptide/DR1 complexes formed in the DO depleted reaction was compared to a reaction containing no DO (left bar in each set of three), and a reaction that contained DO that did not undergo depletion (right bar in each set of three). The experiment is representative of three separate trials. (C) A DO-depleted sample was used instead of DO in a reaction measuring of HA(306–318) peptide/DR complex formation in the presence or absence of DM after 5 hours of incubation. The fluorescence intensity of peptide/DR1 complexes formed in the DO depleted reaction was compared to a reaction containing no DO (left bar in each set of three), and a reaction that contained DO that did not undergo depletion (right bar in each set of three). The experiment is representative of three separate trials.
Figure 6.
HLA-DO affects peptide binding to DR1 independent of DM.
(A) Association kinetics of HA(306–318) to peptide-receptive DR1 without DO (black triangles) or with DO (red triangles). (B) Association kinetics of CII(259–273) to peptide-receptive DR1 without DO (black triangles) or with DO (red triangles). Experiments in A and B are representative of three-four trials. (C) HA(anchorless) association to constitutively receptive mutant DR1βG86Y molecules with no accessory molecules (black squares), with DM (red dots), DO (green triangles) or both DO and DM (blue triangles). The fluorescence signals (Arbitrary Fluorescence Units) associated with the control samples incubated >10 hours in the absence of DR1 were measured: HA(anchorless) peptide alone, 1804; HA(anchorless)+DM, 1512; HA(anchorless)+DO, 2280; HA(anchorless)+DM+DO, 2888.
Figure 7.
HLA-DO interacts with DR1 in a receptive conformation but not a peptide-loaded, compact form.
(A) SPR sensograms of constitutively receptive DR1βG86Y (4µM) binding to DO. Ni-NTA purified DO was immobilized on anti-His antibody coupled chip (blue trace). After a brief wash, DR1βG86Y was injected over the captured DO surface (green trace). An injection of unloaded DR1 over the anti-His antibody surface (red trace) was performed to control for potential nonspecific binding DR1 to the chip surface. (B) SPR sensograms of closed compact DR1/HA(306–318) complex (4µM) binding to DO. Ni-NTA purified DO was immobilized on anti-His antibody coupled chip (blue trace). After a brief wash, DR1/HA(306–318) was injected over the captured DO surface (green trace). An injection of unloaded DR1 over the anti-His antibody surface (red trace) was performed to control for potential nonspecific binding DR1 to the chip surface. (C) DR1βG86Y binding to DM/DO complex molecules. Mags.DO5 purified DM/DO was immobilized on anti-His antibody coupled chip surface to a level of 2000–3000 RU. After a brief wash, DR1βG86Y was injected over the captured DM/DO at concentrations of 0.5 µM (blue trace), 1 µM (red trace), 2 µM (green trace). Before every injection of DR1βG86Y, the DM/DO molecules captured on the surface were regenerated to insure that the surface was not saturated by bound DR1 molecules. The signal of the resulting binding ∼200–300 after the end of the injection is marked on the graph. (D) Binding controls of DR1βG86Y and DR1/HA(306–318) with anti-His antibody, DM/DO and DM surfaces. Following the immobilization of anti-His antibody, 4 µM DR1βG86Y (red trace) and 4 µM DR1/HA(306–318) (black trace) were injected over the immobilized antibody. Upon capturing 2000–3000 RU of DM/DO by the anti-His antibody, 4 µM DR1/HA(306–318) was injected over the DM/DO (green trace). In a separate control, 3000 RU of DM was captured by immobilized anti-FLAG antibody. 4 µM DR1βG86Y (cyan trace), or 4 µM DR1/HA(306–318) (blue trace) was injected over the captured DM. The magnitude of binding was measured at the stability point ∼200–300 seconds after the end of the injection. Data shown are representative of two independent experiments.
Figure 8.
Transiently receptive DR1 molecules interact with DM/DO complexes.
Mags.DO5 purified DM/DO was immobilized on anti-His antibody coupled chip surface to a level of 2000–3000 RU. Receptive DR1 molecules were generated from DR1/HA(Y308A) peptide complexes by removing the excess peptide by G-50 size-exclusion spin columns, adding DM and allowing the peptide to dissociate for 20 minutes at 37°C. Immediately after the 20 minute incubation 4 µM receptive DR1 with 2 µM DM was injected over the captured DM/DO at a rate of 1 µL/min and a constant flow-cell temperature of 37°C for 50 minutes (green trace). As a control, prior to the injection of receptive DR1 molecules, 2 µM DM (blue trace), or 4 µM DR1/HA(306–318) (red trace) were injected at the same flow rate and temperature. Data shown are representative of two independent experiments.
Figure 9.
A model for the effects of HLA-DO on antigen presentation.
DO likely interacts with peptide-receptive DR molecules and may stabilize an overly receptive conformation. This conformation lends itself to a more efficient release of the poorly binding peptides while helping the formation of compact complexes with the well-fitting peptides. In the pool of available peptides those with weak anchoring residues that tend to be more DM-sensitive may not get a chance to stabilize in the groove, and therefore are outcompeted by DM-resistant peptides with bulkier hydrophobic P1 pocket residues. We theorize that DO interacts primarily with DR molecules in receptive conformation mostly generated by the effector function of DM.